Literature DB >> 11064446

Interferon-beta treatment for patients with multiple sclerosis: the patients' perceptions of the side-effects.

K Gottberg1, A Gardulf, S Fredrikson.   

Abstract

The aims of this study were to investigate (i) the self-reported frequency and intensity of systemic side-effects and their impact on the daily lives of patients suffering from Multiple Sclerosis (MS) and undergoing interferon-beta therapy and (ii) the self-reported frequency and perceptions of any local-tissue reactions. Forty patients aged 22 - 59 years (27 females) with relapsing/remitting MS were consecutively recruited for the study (17 on interferon-beta-1a and 23 on interferon-beta-1b). Two self-administered questionnaires were used before and after 1, 4, 8 and 16 weeks of therapy. The interferon therapy was found to be associated with flu-like symptoms. Most systemic side-effects were reported to be mild and to have little impact on the patients' daily lives. Asthenia and fatigue were more often rated as moderate or severe. The most frequently reported local-tissue side-effects were redness and local pain at the injection sites. A considerable inter-individual variation was found among patients regarding the perceptions of both the systemic and local side-effects. This suggests that it is of importance to identify early those patients who may need more support or other interventions to maintain a successful compliance. Multiple Sclerosis (2000) 6 349 - 354

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11064446     DOI: 10.1177/135245850000600510

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  6 in total

1.  Adherence to first-line disease-modifying therapy for multiple sclerosis in kuwait.

Authors:  Raed Alroughani; Anil Thussu
Journal:  Int J MS Care       Date:  2012

Review 2.  Neurobehavioral effects of interferon therapy.

Authors:  Alan D Valentine; Christina A Meyers
Journal:  Curr Psychiatry Rep       Date:  2005-10       Impact factor: 5.285

3.  Commensal Microbiota Modulation of Natural Resistance to Virus Infection.

Authors:  Kailyn L Stefan; Myoungjoo V Kim; Akiko Iwasaki; Dennis L Kasper
Journal:  Cell       Date:  2020-11-18       Impact factor: 41.582

4.  Adverse events of interferon beta-1a: a prospective multi-centre international ICH-GCP-based CRO-supported external validation study in daily practice.

Authors:  Peter Joseph Jongen; Christian Sindic; Evert Sanders; Stanley Hawkins; Wim Linssen; Erik van Munster; Stephan Frequin; George Borm
Journal:  PLoS One       Date:  2011-10-25       Impact factor: 3.240

5.  Injectable interferon beta-1b for the treatment of relapsing forms of multiple sclerosis.

Authors:  Slobodan M Jankovic
Journal:  J Inflamm Res       Date:  2010-03-16

6.  Influence of Interferon beta treatment on quality of life in multiple sclerosis patients.

Authors:  Isabella Laura Simone; Antonia Ceccarelli; Carla Tortorella; Alessandra Bellacosa; Fabio Pellegrini; Immacolata Plasmati; Maria Fara De Caro; Mariangela Lopez; Francesco Girolamo; Paolo Livrea
Journal:  Health Qual Life Outcomes       Date:  2006-12-12       Impact factor: 3.186

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.